6.48
2.86%
+0.18
After Hours:
6.48
Overview
News
Price History
Option Chain
Why GRFS Down?
Discussions
Forecast
Stock Split
Dividend History
Grifols SA ADR stock is currently priced at $6.48, with a 24-hour trading volume of 3.41M.
It has seen a +2.86% increased in the last 24 hours and a +4.18% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.30 pivot point. If it approaches the $6.43 resistance level, significant changes may occur.
Grifols SA ADR Stock (GRFS) Financials Data
Grifols SA ADR (GRFS) Revenue 2024
GRFS reported a revenue (TTM) of $7.21 billion for the quarter ending December 31, 2023, a +15.31% rise year-over-year.
Grifols SA ADR (GRFS) Net Income 2024
GRFS net income (TTM) was $211.12 million for the quarter ending December 31, 2023, a -54.37% decrease year-over-year.
Grifols SA ADR (GRFS) Cash Flow 2024
GRFS recorded a free cash flow (TTM) of $709.16 million for the quarter ending June 30, 2021.
Grifols SA ADR (GRFS) Earnings per Share 2024
GRFS earnings per share (TTM) was $0.3111 for the quarter ending December 31, 2023, a -54.12% decline year-over-year.
Grifols SA ADR Stock (GRFS) Latest News
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
GlobeNewswire Inc.
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Zacks Investment Research
Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírus
GlobeNewswire Inc.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Zacks Investment Research
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
About Grifols SA ADR
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Cap:
|
Volume (24h):